Capecitabine and Celecoxib as Second-Line Treatment of Advanced Pancreatic and Biliary Tract Cancers

Publisher： Karger

E-ISSN： 1423-0232|76|4|254-261

ISSN： 0030-2414

Source： Oncology, Vol.76, Iss.4, 2009-02, pp. : 254-261

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Imatinib Mesylate for Palliative Second-Line Treatment of Advanced Biliary Tract Cancer: A Bicentric Phase II Study

By  

Oncology Research and Treatment, Vol. 34, Iss. 8-9, 2011-08 ,pp. : 469-470

Karger

Access to resources Recommend Favorite

Second‐line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine‐platinum combination: A large multicenter study by the Association des Gastro‐Entérologues Oncologues

By  

CANCER, Vol. 121, Iss. 18, 2015-09 ,pp. : 3290-3297

John Wiley & Sons Inc

Access to resources Recommend Favorite

Capecitabine as Second-Line Treatment for Metastatic Cholangiocarcinoma: A Report of Two Cases

By  

Oncology Research and Treatment, Vol. 25, Iss. 2, 2002-05 ,pp. : 182-184

Karger

Access to resources Recommend Favorite

Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy

By  

Oncology, Vol. 74, Iss. 1-2, 2008-06 ,pp. : 31-36

Karger

Access to resources Recommend Favorite

Second-Line Treatment of Advanced Gastric Cancer with Oxaliplatin plus Raltitrexed

By  

Oncology Research and Treatment, Vol. 26, Iss. 3, 2003-07 ,pp. : 255-258

Karger

Access to resources Recommend Favorite